CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine's Increased Efficacy And Points To Potential For Combination With Checkpoint Inhibitors For Head And Neck Cancer
Portfolio Pulse from Benzinga Newsdesk
CEL-SCI has reported Phase 3 tumor PD-L1 biomarker data showing increased efficacy of Multikine and its potential for combination with checkpoint inhibitors for head and neck cancer. The company has filed a patent for the use of Multikine in tumors expressing low levels of PD-L1.
July 11, 2023 | 12:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CEL-SCI's Phase 3 data shows increased efficacy of Multikine, potentially boosting its market position. The company has also filed a patent for its use in specific tumors, which could provide a competitive edge.
The positive Phase 3 data and the patent filing for Multikine could potentially increase CEL-SCI's market share and provide a competitive advantage. This could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100